SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles - Ting Zhang; Jianyan Xu; Junzhao Yin; Yun Gao; Hanwen Zheng; Beibei Fu; Jiakang Sun; Zhibin Xu; Shiwei Tu; Yuchang Mao; Weiyun Wen; Bolei Qu; et al. (PLoS ONE, 2025)